Postoperative Nausea and Vomiting

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

8 programs

Aprepitant + DexamethasonePhase 41 trial

Aprepitant plus OndansetronPhase 41 trial

Aprepitant, Dexamethasone, OndansetronPhase 41 trial

SugammadexPhase 41 trial

MK0869, aprepitantPhase 31 trial

+3 more programs

Active Trials

NCT00819039Completed98Est. Mar 2013

NCT00539721Completed619Est. Jul 2008

NCT00090155Completed805Est. Nov 2004

+5 more trials

Sharp TherapeuticsPA - Pittsburgh

8 programs

Aprepitant + DexamethasonePhase 4

Aprepitant plus OndansetronPhase 4

Aprepitant, Dexamethasone, OndansetronPhase 4

SugammadexPhase 4

MK0869, aprepitantPhase 3

+3 more programs

Acacia PharmaUK - Cambridge

5 programs

APD421Phase 31 trial

APD405Phase 21 trial

APD421Phase 21 trial

APD421Phase 11 trial

Active Trials

NCT03583489Completed30Est. Aug 2018

NCT00895830Completed257Est. Nov 2009

NCT01510704Completed215Est. Apr 2012

+2 more trials

HelsinnIreland - Dublin

2 programs

PalonosetronPhase 31 trial

palonosetronPhase 31 trial

Active Trials

NCT01395901Completed670Est. Apr 2012

NCT00828295Completed150Est. Jan 2009

ViiV HealthcareNC - Durham

3 programs

GW597599Phase 2

GW679769Phase 2

intravenous ondansetronPhase 2

UNION therapeuticsDenmark - Hellerup

2 programs

electrical stimualtion via EmeTerm braceletPhase 21 trial

Surgeries for gynecologic diseaseN/A1 trial

Active Trials

NCT03795766Unknown1,000Est. Jan 2021

NCT06241547Active Not Recruiting302Est. Mar 2026

GSKLONDON, United Kingdom

3 programs

GW597599PHASE_21 trial

GW679769PHASE_21 trial

intravenous ondansetronPHASE_21 trial

Active Trials

NCT00600990Completed624Est. Jul 2006

NCT00274690Completed435Est. Aug 2005

NCT00108095Completed701Est. Aug 2005

EisaiChina - Liaoning

2 programs

OndansetronPHASE_21 trial

Palonosetron 0.075 mg IVPHASE_41 trial

Active Trials

NCT00967499Completed239Est. Dec 2009

NCT02635828Completed40Est. Oct 2011

Stuart TherapeuticsFL - Stuart

1 program

Aromatherapy inhalerPHASE_21 trial

Active Trials

NCT02663154Completed39Est. Jul 2015

Qilu PharmaceuticalChina - Jinan

1 program

Aprepitant InjectionPHASE_31 trial

Active Trials

NCT06932107Completed518Est. Jun 2024

City TherapeuticsMA - Cambridge

1 program

GlycopyrroniumPHASE_41 trial

Active Trials

NCT05265507UnknownEst. May 2023

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

City TherapeuticsGlycopyrronium

MSDSugammadex

EisaiPalonosetron 0.075 mg IV

MSDAprepitant, Dexamethasone, Ondansetron

MSDAprepitant plus Ondansetron

MSDAprepitant + Dexamethasone

Qilu PharmaceuticalAprepitant Injection

Acacia PharmaAPD421

HelsinnPalonosetron

Helsinnpalonosetron

MSDMK0869, aprepitant

UNION therapeuticselectrical stimualtion via EmeTerm bracelet

Stuart TherapeuticsAromatherapy inhaler

Showing 15 of 25 trials with date data

Clinical Trials (25)

Total enrollment: 9,370 patients across 25 trials

NCT05265507 City TherapeuticsGlycopyrronium

Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron

Start: Mar 2022Est. completion: May 2023

Phase 4Unknown

NCT03276026 MSDSugammadex

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

Start: Feb 2018Est. completion: Nov 201868 patients

Phase 4Terminated

NCT02635828 EisaiPalonosetron 0.075 mg IV

Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis

Start: Oct 2009Est. completion: Oct 201140 patients

Phase 4Completed

NCT00738621 MSDAprepitant, Dexamethasone, Ondansetron

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

Start: Jul 2008Est. completion: Aug 2010100 patients

Phase 4Completed

NCT00659945 MSDAprepitant plus Ondansetron

Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery

Start: Jun 2008Est. completion: Jun 2010150 patients

Phase 4Completed

NCT00734929 MSDAprepitant + Dexamethasone

Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy

Start: Sep 2007Est. completion: Jun 2009115 patients

Phase 4Completed

NCT06932107 Qilu PharmaceuticalAprepitant Injection

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Start: Feb 2024Est. completion: Jun 2024518 patients

Phase 3Completed

NCT02646566 Acacia PharmaAPD421

Study of APD421 as PONV Treatment (Prior Prophylaxis)

Start: Mar 2016Est. completion: Jan 2017705 patients

Phase 3Completed

NCT02449291 Acacia PharmaAPD421

Study of APD421 as PONV Treatment (no Prior Prophylaxis)

Start: Sep 2015Est. completion: Jul 2016568 patients

Phase 3Completed

NCT01395901 HelsinnPalonosetron

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Start: Jun 2011Est. completion: Apr 2012670 patients

Phase 3Completed

NCT00828295 Helsinnpalonosetron

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Start: Aug 2008Est. completion: Jan 2009150 patients

Phase 3Completed

NCT00090246 MSDMK0869, aprepitant

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

Start: May 2004Est. completion: Apr 2005922 patients

Phase 3Completed

NCT00090155 MSDMK0869, aprepitant

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)

Start: Sep 2003Est. completion: Nov 2004805 patients

Phase 3Completed

NCT06241547 UNION therapeuticselectrical stimualtion via EmeTerm bracelet

PONV Prevention Via Percutaneous Nerve Electrical Stimulation on PC6

Start: Jan 2024Est. completion: Mar 2026302 patients

Phase 2Active Not Recruiting

NCT02663154 Stuart TherapeuticsAromatherapy inhaler

Aromatherapy for Postoperative Nausea and Vomiting in Children

Start: Jul 2014Est. completion: Jul 201539 patients

Phase 2Completed

NCT01510704 Acacia PharmaAPD421

Phase II Dose-ranging Study of APD421 in PONV

Start: Jan 2012Est. completion: Apr 2012215 patients

Phase 2Completed

NCT00967499 EisaiOndansetron

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

Start: Jul 2009Est. completion: Dec 2009239 patients

Phase 2Completed

NCT00895830 Acacia PharmaAPD405

Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)

Start: May 2009Est. completion: Nov 2009257 patients

Phase 2Completed

NCT00539721 MSDRolapitant Dose 1

A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)

Start: Oct 2007Est. completion: Jul 2008619 patients

Phase 2Completed

NCT00274690 GSKGW679769

Post-Operative Nausea And Vomiting Study In Female Patients

Start: Feb 2005Est. completion: Aug 2005435 patients

Phase 2Completed

NCT00600990 GSKGW597599

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

Start: Dec 2004Est. completion: Jul 2006624 patients

Phase 2Completed

NCT00108095 GSKintravenous ondansetron

A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting

Start: Oct 2004Est. completion: Aug 2005701 patients

Phase 2Completed

NCT03583489 Acacia PharmaAPD421

Study of APD421 With and Without Ondansetron

Start: Jul 2018Est. completion: Aug 201830 patients

Phase 1Completed

NCT00819039 MSDAprepitant

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

Start: Jan 2009Est. completion: Mar 201398 patients

Phase 1Completed

NCT03795766 UNION therapeuticsSurgeries for gynecologic disease

Nausea and Vomiting After Gynecologic Surgery

Start: Jan 2019Est. completion: Jan 20211,000 patients

N/AUnknown

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs, potential near-term approvals

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.